Scholarlink

Background <p><i>I’m Cryptococcus neoformans</i> is an opportunistic fungal pathogen that primarily affects immunocompromised individuals, particularly those with advanced HIV/AIDS. However, an increasing number of cases are being identified in non-HIV immunocompromised hosts, including patients receiving B-cell-depleting therapies such as Rituximab.</p> Case presentation <p>A 67-year-old male with marginal B-cell lymphoma developed an isolated cryptococcal bloodstream infection shortly after completing Rituximab therapy. Initially, the patient presented with persistent diarrhea and progressive weakness. Subsequently, acute otitis media developed, and Streptococcus pneumoniae bacteremia was diagnosed. During his hospital course, his repeated blood cultures were cleared of bacteria but revealed <i>Cryptococcus neoformans</i>, confirmed by a positive serum cryptococcal antigen (titer 1:40). Given the patient’s severe coagulopathy, a lumbar puncture was not feasible, necessitating an alternative diagnostic approach. Adhering to IDSA guidelines, he received a 2-week induction phase of amphotericin B and flucytosine, followed by consolidation and maintenance therapy with fluconazole. The patient successfully completed his induction therapy as an inpatient without complications and demonstrated clinical recovery at a subsequent follow-up visit.</p> Conclusion <p>This case study highlights the expanding spectrum of cryptococcosis beyond HIV/AIDS and underscores the paramount importance of early recognition and treatment, adhering to established guidelines, in the context of Rituximab-associated immunosuppression. Further research is needed to refine risk stratification of isolated <i>Cryptococcus</i> bloodstream infection and develop tailored management strategies for this emerging at-risk population.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Isolated cryptococcus bloodstream infection in a non-HIV patient following rituximab therapy for B-Cell lymphoma: a therapeutic challenge and literature review

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月20日

查看全文
  • Imad Majeed,
  • Ajsa Karacic,
  • Asim Ali,
  • Muddasir Mehmood Jan,
  • David Thomas

摘要

Background

I’m Cryptococcus neoformans is an opportunistic fungal pathogen that primarily affects immunocompromised individuals, particularly those with advanced HIV/AIDS. However, an increasing number of cases are being identified in non-HIV immunocompromised hosts, including patients receiving B-cell-depleting therapies such as Rituximab.

Case presentation

A 67-year-old male with marginal B-cell lymphoma developed an isolated cryptococcal bloodstream infection shortly after completing Rituximab therapy. Initially, the patient presented with persistent diarrhea and progressive weakness. Subsequently, acute otitis media developed, and Streptococcus pneumoniae bacteremia was diagnosed. During his hospital course, his repeated blood cultures were cleared of bacteria but revealed Cryptococcus neoformans, confirmed by a positive serum cryptococcal antigen (titer 1:40). Given the patient’s severe coagulopathy, a lumbar puncture was not feasible, necessitating an alternative diagnostic approach. Adhering to IDSA guidelines, he received a 2-week induction phase of amphotericin B and flucytosine, followed by consolidation and maintenance therapy with fluconazole. The patient successfully completed his induction therapy as an inpatient without complications and demonstrated clinical recovery at a subsequent follow-up visit.

Conclusion

This case study highlights the expanding spectrum of cryptococcosis beyond HIV/AIDS and underscores the paramount importance of early recognition and treatment, adhering to established guidelines, in the context of Rituximab-associated immunosuppression. Further research is needed to refine risk stratification of isolated Cryptococcus bloodstream infection and develop tailored management strategies for this emerging at-risk population.